May 16, 2025

Novel Prediction Model for Hearing Loss From Chemotherapy in Pediatric Patients With Cancer

In a study reported in the Journal of Clinical Oncology, Millstein et al attempted to develop a predictive model—Pediatric Holistic Evaluation of Auditory Risk (PedsHEAR)—for hearing loss associated w...

The ASCO Post

May 16, 2025

Retifanlimab-dlwr Approved for Anal Cancer

The FDA approved the PD-1–blocking monoclonal antibody in combination with carboplatin and paclitaxel for the first-line treatment of adults with inoperable locally recurrent or metastatic squamous ce...

The ASCO Post

May 16, 2025

Neoadjuvant Therapy for IBD-Related Rectal Cancer

Total neoadjuvant therapy was shown to be less effective for treating patients with rectal cancer with inflammatory bowel disease (IBD) than those with sporadic rectal cancer, according to study findi...

The ASCO Post

May 16, 2025

Second-Line Endocrine Therapy With/Without Palbociclib Rechallenge in HR-Positive, HER2-Negative Advanced Breast Cancer

In a phase II trial (PALMIRA) reported in the Journal of Clinical Oncology, Llombart-Cussac et al evaluated whether palbociclib rechallenge with second-line alternative endocrine therapy improved prog...

The ASCO Post

May 15, 2025

Chemotherapy-Free Triplet in Previously Treated HR-Positive, HER2-Positive Advanced Breast Cancer

In a phase IIa study reported in The Lancet Oncology, Escrivá-de-Romani et al evaluated whether the chemotherapy-free triplet of the HER2-targeted bispecific antibody zanidatamab plus palbociclib and ...

The ASCO Post

May 15, 2025

Circulating Tumor DNA–Guided Risk Stratification in Colorectal Cancer: Evolving Evidence and Future Utility

Circulating tumor DNA (ctDNA) has emerged as a promising biomarker in colorectal cancer, offering dynamic insight into disease burden and recurrence risk. However, questions remain about its clinical ...

The ASCO Post

May 15, 2025

Afatinib vs Chemotherapy in NSCLC With Uncommon Activating EGFR Mutations

In an interim analysis of a Japanese trial (ACHILLES/TORG1834) reported in the Journal of Clinical Oncology, Miura et al evaluated whether afatinib prolonged progression-free survival vs platinum-base...

The ASCO Post

May 14, 2025

First-Line TFOX vs FOLFOX in Advanced HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma

In a French phase III trial (PRODIGE 51-FFCD-GASTFOX) reported in The Lancet Oncology, Zaanan et al explored whether a modified FLOT (fluorouracil, oxaliplatin, and docetaxel) regimen known as TFOX (d...

The ASCO Post

May 14, 2025

FDA OCE Announces Project Interface Outreach Initiative

The Oncology Center of Excellence (OCE) at the FDA has launched Project Interface to advance engagement and outreach to patients with cancer, advocacy organizations, and oncology experts. Its mission ...

The ASCO Post